172 related articles for article (PubMed ID: 36096078)
21. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.
Schmitz MF; Otten HG; Franssen LE; van Dorp S; Strooisma T; Lokhorst HM; van de Donk NW
Haematologica; 2014 Dec; 99(12):1846-53. PubMed ID: 25193963
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
23. Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study.
Sgherza N; Curci P; Rizzi R; Strafella V; Di Gennaro D; Vitucci A; Palma A; Rossi AVR; Albano F; Stefanizzi P; Tafuri S; Musto P
Haematologica; 2022 Feb; 107(2):555-557. PubMed ID: 34732044
[No Abstract] [Full Text] [Related]
24. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of monoclonal gammopathy of undetermined significance in US black women.
Bertrand KA; Zirpoli G; Niharika Pillalamarri B; Szalat R; Palmer JR; Kataria Y
Am J Hematol; 2022 Sep; 97(9):E341-E343. PubMed ID: 35723873
[No Abstract] [Full Text] [Related]
26. When a Monoclonal Gammopathy Is Not Multiple Myeloma.
Derman B; Castillo JJ; Sarosiek S; Beksac M
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35394823
[TBL] [Abstract][Full Text] [Related]
27. Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.
Sigurbergsdóttir AÝ; Love TJ; Kristinsson SY
Front Immunol; 2022; 13():876271. PubMed ID: 35572590
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
29. Resolution of dysglycaemia after treatment of monoclonal gammopathy of endocrine significance.
Grant B; Ratnayake G; Williams CL; Long A; Halsall DJ; Semple RK; Cavenagh JD; Drake WM; Church DS
Eur J Endocrinol; 2023 Dec; 189(6):K25-K29. PubMed ID: 37818852
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.
Kristinsson SY; Tang M; Pfeiffer RM; Björkholm M; Goldin LR; Blimark C; Mellqvist UH; Wahlin A; Turesson I; Landgren O
Haematologica; 2012 Jun; 97(6):854-8. PubMed ID: 22180421
[TBL] [Abstract][Full Text] [Related]
31. [Monoclonal gammopathy of undetermined significance with recurrent skin bleeding: a case report].
Xiao YY; Zhang Y; Cao C; Luo Y; Lou SF
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1050. PubMed ID: 36709114
[No Abstract] [Full Text] [Related]
32. MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort.
Da Vià MC; Lionetti M; Marella A; Matera A; Travaglino E; Signaroldi E; Galbussera AA; Lucca U; Mandelli S; Riva E; Tettamanti M; Pettine L; Pompa A; Baldini L; Neri A; Della Porta MG; Bolli N
Blood Adv; 2022 Nov; 6(21):5702-5706. PubMed ID: 35390146
[TBL] [Abstract][Full Text] [Related]
33. Acquired von willebrand syndrome secondary to monoclonal gammopathy of undetermined significance: long-term remission after treatment with bortezomib.
Saldanha A; Veiga ME; Okazaki E; Rothschild C; Martinez G; Rocha V; Orsi FA; Villaca P
J Thromb Thrombolysis; 2023 May; 55(4):770-774. PubMed ID: 37000318
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.
Cicero KI; Joffe M; Patel M; Chiuzan C; Pentz A; Ruff P; Lentzsch S; Leng S; Jacobson JS; Rebbeck TR; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2192-2198. PubMed ID: 36126958
[TBL] [Abstract][Full Text] [Related]
35. AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"?
Terré A; Colombat M; Cez A; Martin C; Diet C; Brechignac S; Oghina S; Bodez D; Faguer S; Savey L; Galland J; Boffa JJ; Grateau G; Jaccard A; Buob D; Georgin-Lavialle S
Int J Clin Pract; 2021 Nov; 75(11):e14817. PubMed ID: 34490695
[TBL] [Abstract][Full Text] [Related]
36. Does my patient with a serum monoclonal spike have multiple myeloma?
Bianchi G; Ghobrial IM
Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous manifestations of dysproteinemias.
Dominey AM; Tschen JA
Dermatol Clin; 1989 Jul; 7(3):449-66. PubMed ID: 2502337
[TBL] [Abstract][Full Text] [Related]
38. Spinal cord compression in monoclonal gammopathy of undetermined significance.
Bernardeschi P; Fiorentini G; Dentico P; Rossi S
Br J Haematol; 2004 Feb; 124(4):561-2. PubMed ID: 14984512
[No Abstract] [Full Text] [Related]
39. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.
Landgren O
Hematology Am Soc Hematol Educ Program; 2010; 2010():295-302. PubMed ID: 21239809
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Rev Clin Exp Hematol; 2002 Sep; 6(3):225-52. PubMed ID: 12616697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
